Group by Gene: Include preclinical: Chemotherapy DNA BCL Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy PARP Inhibitors | PD1 inhibitor cemiplimab-rwlc | pembrolizumab | Bifunctional alkylating agent ifosfamide | Topoisomerase II inhibitor etoposide IV | Tubulin polymerization promoter carboplatin | Topoisomerase II inhibitor, DNA inhibitor etoposide oral | DNA synthesis inhibitor cisplatin | CLDN6-targeted CAR-T immunotherapy BNT211 | PARP inhibitor talazoparib | Microtubule inhibitor, CLDN6-targeted antibody-drug conjugate TORL-1-23 | IMAB027-vcMMAE | TI-CE | TIP | VIP | Chemotherapy GemOx | VeIP | EP | GemPOx | BEP | Topoisomerase II inhibitor, Tubulin polymerization promoter carboplatin + etoposide IV | Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor gemcitabine + paclitaxel |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | |||||||||||||||||||||
TMB-H | |||||||||||||||||||||
MSI-H/dMMR | |||||||||||||||||||||
CLDN6 expression | |||||||||||||||||||||
CHEK2 mutation |